Innovent catching up with Lilly, Novo Nordisk thanks to phase 2 obesity data

Innovent is catching up with the likes of Eli Lilly and Novo Nordisk as the Chinese pharma’s own obesity drug sailed past the primary endpoint of a phase 2 trial.

The study assessed the effects of the drug, mazdutide, in 230 Chinese participants who were overweight or obese. The proportion of individuals with 5% or more body weight loss from baseline after 24 weeks was 58.1% for those taking a 3-mg dose, 82.5% taking 4.5 mg and 80.3% on 6 mg, compared with 4.8% with placebo.